We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SATS:NASDAQEchoStar Corporation Analysis

Data as of 2026-05-20 - not real-time

$136.52

Latest Price

8/10Risk

Risk Level: High

Executive Summary

EchoStar (SATS) is trading at $136.52, comfortably above its 20‑day ($126.15), 50‑day ($121.86) and 200‑day ($93.63) moving averages, with a bullish MACD histogram (+1.23) and an RSI of 63 indicating upward momentum but no immediate overbought condition. Volume is on the rise and the price sits near the upper end of its 116.32 support / 147.25 resistance band, while the 30‑day volatility of 50% and a computed beta of 1.75 suggest the stock is both highly volatile and more sensitive to market swings. Extreme Greed on the fear‑greed index further underscores strong speculative appetite.
Fundamentally, the company is under pressure: revenue fell 5.2% to $14.8 B, profit margin is –97.5%, and debt‑to‑equity is an alarming 515, leaving a negative ROE of –112% and negligible free cash flow. Recent news shows mixed Q1 earnings—revenue beat estimates but earnings missed—while FCC approval of $40 B worth of spectrum sales to SpaceX and AT&T provides a potential catalyst to improve the balance sheet. Despite the technical upside, the heavy debt load, ongoing losses, and lack of dividend make the valuation appear stretched.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish technical setup (price above SMAs, MACD bullish, rising volume)
  • FCC approval of large spectrum sales unlocking >$40 B
  • Market sentiment in extreme greed phase

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Need to deploy proceeds from spectrum sales to reduce debt
  • Continued revenue decline and negative earnings
  • High leverage limiting operational flexibility

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Long‑term growth prospects in satellite broadband and 5G services
  • Persistent balance‑sheet weakness and cash‑flow deficits
  • Industry cyclicality and competitive pressure

Key Metrics & Analysis

Financial Health

Revenue Growth-5.20%
Profit Margin-97.56%
P/E Ratio-1197.5
ROE-112.28%
ROA0.40%
Debt/Equity515.06
P/B Ratio6.8
Op. Cash Flow$-67845000
Free Cash Flow$-457875616
Industry P/E17.1

Technical Analysis

TrendBullish
RSI63.2
Support$116.32
Resistance$147.25
MA 20$126.15
MA 50$121.86
MA 200$93.63
MACDBullish
VolumeIncreasing
Fear & Greed Index89.25

Valuation

Target Price$134.80
Upside/Downside-1.26%
GradeOvervalued
TypeValue

Risk Assessment

Beta1.75
Volatility50.39%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.